Co-expression of plasmid-based protein kinase B1-specific small interfering RNA and P53 synergistically inhibits proliferation, migration and invasion of hepatocellular carcinoma cells

CHEN Xiao-Long; WAN Ya-Feng; HUANG Ping

doi:10.16098/j.issn.0529-1356.2021.02.014

PDF(6293 KB)

Acta Anatomica Sinica ›› 2021, Vol. 52 ›› Issue (2) : 251-257. DOI: 10.16098/j.issn.0529-1356.2021.02.014

Co-expression of plasmid-based protein kinase B1-specific small interfering RNA and P53 synergistically inhibits proliferation, migration and invasion of hepatocellular carcinoma cells

CHEN Xiao-long¹WANG Ya-feng² HUANG Ping^1*

Author information +

History +

Abstract

Objective To investigate the effect of the dual expression plasmid of protein kinase B1(Akt1)-specific siRNA and P53 on the proliferation, migration, invasion and apoptosis of hepatocellular carcinoma (HCC) cells. Methods We constructed a dual expression plasmid that co-expressed Akt1-specific siRNA and wild-type p53 gene (pSi-Akt1-P53).The dual expression plasmid pSi-Akt1-P53 was transfected into HepG2 cells of HCC,The expression of Akt1 and P53 was detected by Real-time PCR and Western blotting. Then, the dual expression plasmid was transfected into HepG2 cells, sh-Akt1 plasmid and P53 plasmid were used as control. The effects of the dual plasmid on the proliferation, migration, invasion and apoptosis of HepG2 cells were detected by CCK-8 and 5-ethynyl-2’-deoxyuridine(EdU) experiments, Wound scratch experiment, Transwell chamber experiment and flow cytometry,respectively. Results After the dual plasmid was transfected into HepG2 cells, the expression of Akt1 protein was significantly reduced and the expression of P53 protein was significantly increased in HepG2 cells. Compared with the shAkt1 and P53 plasmids, the dual expression plasmid pSi-Akt1-P53 significantly inhibited the proliferation、migration and invasion of HepG2 cells and significantly increased the apoptosis of HepG2 cells. Conclusion The dual expression plasmid pSi-Akt1-P53 can synergistically inhibit the proliferation, migration and invasion of HepG2 cells, significantly increased the apoptosis of HepG2 cells.

Key words

Hepatocellular carcinoma / Dual expression plasmid / Protein kinase B1 / P53 / Real-time PCR / Human

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

CHEN Xiao-long WANG Ya-feng HUANG Ping. Co-expression of plasmid-based protein kinase B1-specific small interfering RNA and P53 synergistically inhibits proliferation, migration and invasion of hepatocellular carcinoma cells[J]. Acta Anatomica Sinica. 2021, 52(2): 251-257 https://doi.org/10.16098/j.issn.0529-1356.2021.02.014

References

［1］ Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma ［J］. Lancet, 2003, 362(9399): 1907-1917.

［2］ Yang T, Zhang J, Lu JH, et al. A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort ［J］. J Cancer Res Clin Oncol, 2011, 137 (5):739-750.

［3］ Aylon Y, Oren M. Living with p53, dying of p53 ［J］. Cell, 2007, 130(4): 597-602.

［4］ Carmer E, Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death ［J］. Cell Cycle, 2008, 7(3): 277-282.

［5］ Lin ZhX, Zhang PF, Jiang CZh, et al. The exploration of relationship between immunohistochemistry of LN, FN, p53 and tumorous invasion microecosystem in human brain glioma ［J］. Acta Anatomica Sinica，2002，33(4): 360-365. (in Chinese)

林志雄，张鹏飞，江常震，等. 人脑胶质瘤中LN、FN及p53基因蛋白的免疫组织化学与其侵袭微生态系统的相关性探讨［J］. 解剖学报，2002，33(4): 360-365.

［6］ Soussi T, Ishioka C, Claustres M, et al．Locus-specific mutation databases: pitfalls and good practice based on the p53 experience ［J］. Nat Revi Cancer, 2006, 6(1): 83-90.

［7］ Cancer Genome Atlas Research Network, Electronic address:wheeler@bcm.edu. Comprehensive and integrative genomic characterization of hepatocellular carcinoma ［J］. Cell, 2017, 169(7): 1327-1341.

［8］ Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase Akt pathway in human cancer ［J］. Nat Rev Cancer, 2002, 2(7), 489-501.

［9］ Sheppard K, Kinross KM, Solomon B, et al. Targeting PI3 kinase/Akt/mTOR signaling in cancer ［J］. Crit Rev Oncog, 2012, 17(1): 69-95.

［10］ Kornelius S, Sandrine I, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets ［J］. Nat Genet, 2015, 47(5): 505-511.

［11］ Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/Akt-a major therapeutic target ［J］. Biochim Biophys Acta, 2004, 1697(1-2): 3-16.

［12］ Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer ［J］. Cell cycle, 2009, 8(16): 2502-2508.

［13］ Su JS, Woods SM, Ronen SM. Metabolic consequences of treatment with Akt inhibitor perifosine in breast cancer cells ［J］. NMR Biomed, 2012, 25(2): 379-388.

［14］ Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene ［J］. Genes Dev, 2001, 15(17): 2203-2208.

［15］ Cho H, Thorvaldsen JL, Chu Q, et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice ［J］. J Biol Chem, 2001, 276(42): 38349-38352.

［16］ Hartmann W, Digonsontgerath B, Koch A, et al. Phosphatidylinositol 3’-kinase/Akt signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN［J］. Clin Cancer Res, 2006, 12(10): 3019-3027.

［17］ Suzuki Y, Toquenaga Y. Effects of information and group structure on evolution of altruism: analysis of two-score model by Covariance and contextual analyses ［J］. J Theor Bio, 2005, 232(2): 191-201.

［18］ Mottet D, Dumont V, Deceache Y, et al. Regulation of hypoxia-inducible factor-1 alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta pathway in HepG2 cells ［J］．J Biol Chem, 2003, 278(33): 31277-31285.

［19］ Liu L, Zhu S, Gong I, et al. K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis ［J］. PLoS One, 2008, 3(8): e2850．

［20］ Hernandez A, lcoceba R, Sangro B, et al. Genetherapy of liver cancer ［J］. Ann Hepatol, 2007, 6(1): 5-14.

［21］ Bourdon JC, Laurenzi VD, Melion G, et al. p53: 25 years of research And more questions to answer ［J］. Cell Death Differ, 2003, 10(4): 397-399.

［22］ Senzer N, Nemunaitis J, Nemunaitis D, et al. Phase Ⅰ study of a systemically delivered p53 nanoparticle in advanced solid tumors ［J］. Mol Ther, 2013, 21(5): 1096-1103.

［23］ Cheson BD. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma ［J］. N Engl J Med, 2014, 370(11): 1008-1018.

［24］ Zhang L, Gao L, Li Y, et al. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth ［J］. Clin Cancer Res,2008, 14(2): 559-568.

［25］ Wang GM, Ren ZX, Wang PS, et al. Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo ［J］. Oncol Rep,2014, 32(2): 573-580.

［26］ Li X, Li Y, Hu J, et al. Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivo ［J］. Cancer Lett, 2013, 335(1): 242-250.